Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

ResolVE-XAS Addressing Unknowns and Unmet Needs of VEXAS Syndrome by Multiomics Clonal Tracking and Targeted Gene Editing

Coordinator
Ospedale San Raffaele SRL, Italy
Runs
1 March 2025 to 28 February 2030
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101165007

What the project is doing

In the project's own words, from its summary on CORDIS.

Hematopoietic stem cells (HSCs) accumulate somatic mutations during aging, which may drive clonal expansion of their progeny. This clonal imbalance promotes cancer and often establish systemic inflammation contributing to frequent diseases of aging. Disentangling and tackling clonal imbalance of hematopoiesis is thus an urgent challenge with substantial medical implications for a progressively aging population. VEXAS syndrome is a novel, adult-onset, devastating disease with growing number of patients.

It is caused by the expansion of pro-inflammatory hematopoietic clones acquiring somatic mutations of the UBA1 gene. Its pathophysiology is elusive, and treatments are unsatisfactory leading to dismal prognosis. In this project I will address knowledge gaps and unmet medical needs of VEXAS syndrome, here proposed as paradigmatic example of a hematologic disease of aging caused by clonal expansion. To unveil the uncharted pathogenesis underlying VEXAS clonal expansion and inflammation I will develop and apply to patients’ samples innovative multiomics technologies simultaneously informing on phenotype and genetic mutations of clones while reconstructing hierarchical relationships and retrospectively tracing expansion dynamics.

To validate these findings in stringent settings I will leverage cutting-edge gene editing systems for the generation of VEXAS models by installing in human wild-type HSCs the pathogenic mutations found in patients, and study differentiation, clonal expansion and inflammatory properties of their outgrowth in transplanted immunodeficient mice. Finally I will investigate an autologous HSC gene editing approach in VEXAS models based on the hypothesis that targeted disruption or correction of mutant UBA1 alleles can erase fitness advantage of pathogenic clones.

This project will transform current understanding and management of clonal imbalance of hematopoiesis by developing new models and technologies and proposing ambitious strategies to tackle it.

Topics

Who is involved

OrganisationCityCountryRole
Ospedale San Raffaele SRLMilanoItalyCoordinator
Universita Vita-Salute San RaffaeleMilanoItalyThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI